DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Inclisiran
Inclisiran
Download This PDF File
Intervention to Improve LDL Receptor Function Emerging Therapies
Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
Assessment Report
The Effectiveness and Value of Bempedoic Acid and Inclisiran for Heterozygous Familial Hypercholesterolemia and Secondary Prevention of ASCVD
Inclisiran 284Mg Solution for Injection in Pre-Filled Syringe (Leqvio®)
December 11, 2020 Maggie O'grady Program Manager Institute For
The Current Landscape of Nucleic Acid Therapeutics
Inclisiran: a New Promising Agent in the Management of Hypercholesterolemia
Riktige Legemidler Til Rett Pris Områdegjennomgang Av Legemidler Under Folketrygden
Download Info Sheet
Lipidology Trials - What’S New and What’S in the Pipeline?
A Critical Review of the Efficacy and Safety of Inclisiran
PCSK9 and the Gut-Liver-Brain Axis: a Novel Therapeutic Target for Immune Regulation in Alcohol Use Disorder
A21-13 Inclisiran (Primary Hypercholesterolaemia Or Mixed Dyslipidaemia) – Benefit Assessment According to §35A Social Code Book V1
Download the Presentation
Evolving Worldwide Approaches to Lipid Management and Implications for Australian General Practice
Study Protocol
Top View
Novartis Receives EU Approval for Leqvio®* (Inclisiran), a First-In-Class Sirna to Lower Cholesterol with Two Doses a Year**
Inclisiran Lowers LDL-C and PCSK9 Irrespective Of
Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
Treatment of Dyslipidaemia in Children
The Clinical Landscape of Synthetic Gene Silencing Drugs
Review of LDL-C Lowering with Focus on New and Emerging Agents
Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status
Emerging Technologies and Therapeutics Reports
Inclisiran and Bempedoic Acid for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
Minutes of the CHMP Meeting 12-15 October 2020
Lowering LDL Cholesterol with Nonstatin Treatments
“S3-13: Lipids: Looking Forward to 2018”
[email protected]
New Trends in Dyslipidemia Treatment
(CHMP) Agenda for the Meeting on 12-15 October 2020
Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
B.C. Pharmacare Drug Information Sheet for Inclisiran
Mediated Cardiovascular Disease: the Emerging Potential of RNA
Study Protocol 1002-047 Amendment 3, 09 May 2017
A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists
Inclisiran Sodium Equivalent to 284 Mg Inclisiran in 1.5 Ml Solution
A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients
Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach